 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Supplement Article |
*Department of Nephrology, Monash Medical Centre; Department of Epidemiology and Preventive Medicine, Monash University; and International Diabetes Institute, Melbourne, Australia.
Correspondence to Professor Robert Atkins, Department of Nephrology, Monash Medical Centre, 265 Clayton Road, Clayton, Victoria, Australia. Phone: 61-3-9594-3518; Fax: 61-3-9594-6530;
 |
Abstract |
|---|
 Top Abstract IntroductionParticipants and MethodsResultsDiscussionReferences |
|---|
0.20 mg/mg); hematuria—spot urine dipstick (abnormal: 1+ or greater) confirmed by urine microscopy (abnormal: >10,000 red blood cells per milliliter) or dipstick (abnormal: 1+ or greater) on midstream urine sample; and reduced GFR—Cockcroft-Gault estimated GFR (abnormal: <60 ml/min per 1.73 m2). The associations between age, gender, diabetes mellitus, and hypertension, and indicators of kidney damage were examined. Proteinuria was detected in 2.4% of cases (95% CI: 1.6%, 3.1%), hematuria in 4.6% (95% CI: 3.8%, 5.4%), and reduced GFR in 11.2% (95% CI: 8.6%, 13.8%). Approximately 16% had at least one indicator of kidney damage. Age, diabetes mellitus, and hypertension were independently associated with proteinuria; age, gender, and hypertension with hematuria; and age, gender, and hypertension with reduced GFR. Approximately 16% of the Australian adult population has either proteinuria, hematuria, and/or reduced GFR, indicating the presence of kidney damage. Identifying and targeting this section of the population may provide a means to reduce the burden of ESRD. E-mail: bob.atkins@med.monash. edu.au |
Introduction |
|---|
|
TopAbstractIntroductionParticipants and MethodsResultsDiscussionReferences |
|---|
ESRD is usually the result of slowly progressive kidney damage. Due to the asymptomatic nature of renal disease, kidney damage frequently remains undetected until late in the course, at which stage therapeutic interventions are often ineffective. In contrast, early detection and intervention may slow or halt the decline toward ESRD (6). The presence of kidney damage may be indicated by proteinuria, hematuria, or reduced GFR. Individuals with one or more of these indicators of renal disease are known to be at an increased risk of ESRD (7). However, the prevalence of indicators of kidney damage in the general population is not accurately known and the prevalence of early renal disease is probably underestimated. Such data are of vital importance in furthering our understanding of the evolution of renal disease, in planning health resource allocation, and in attempting to reduce the incidence of ESRD.
We therefore performed a population-based survey to define the prevalence of indicators of kidney damage in the general Australian population.
|
Participants and Methods |
|---|
|
TopAbstractIntroductionParticipants and MethodsResultsDiscussionReferences |
|---|
Outcome Measures
All subjects attended a local screening venue and completed a series of questionnaires, physical examinations, and specific laboratory tests examining diabetic status, cardiovascular risk factors, and kidney function. Blood specimens collected were centrifuged on-site and transported daily with urine samples to the central laboratory (HITECH Pathology).
Proteinuria.
Urine protein and creatinine were measured on a morning spot urine sample. Urine protein was measured using pyrogallol red-molybdate by the Olympus AU600 auto-analyser; the coefficient of variation was <4.1%. Urine creatinine were measured by the modified kinetic Jaffe reaction using the Olympus AU600 auto-analyser and the coefficient of variation was <1.1%. Proteinuria was defined in terms of urine protein to creatinine ratio, and values of 0.20 mg/mg or greater (approximating 250 mg/24 h) were considered abnormal (9,10).
Hematuria.
Dipstick testing of morning spot urine samples was performed. Subjects recording zero or trace positive for blood were considered normal, and those with 1+ or greater were asked to provide a midstream urine sample, which was transported to a central laboratory and examined by repeat dipstick and urine microscopy. Subjects with 10,000 or more red bood cells per milliliter by microscopy or with a repeat positive dipstick (1+ or greater) were considered abnormal.
Estimated GFR.
Blood was collected by venipuncture after an overnight fast. Serum creatinine was measured by the modified kinetic Jaffe reaction using the Olympus AU600 auto-analyser and the coefficient of variation was <1.9%. The Cockcroft-Gault method was used to estimate creatinine clearance (11). Adjustment for body surface area was made using the formula: weight (0.425) x height (0.725) x 0.20247 m2 (12). Cockcroft-Gault estimates of creatinine clearance, when corrected for body surface area, have been found to correlate well with gold-standard measures of GFR in studies examining a similar range of subjects to those studied in AusDiab, including those with type 2 diabetes mellitus, the obese, and the ambulatory elderly (13–16). Renal impairment was defined as estimated GFR less than 60 ml/min per 1.73 m2.
Diabetes Status.
All participants, except those with a known diagnosis of diabetes mellitus who were taking hypoglycemic medications, were given a standard 75-g oral glucose tolerance test after collection of a blood specimen after an overnight fast of at least 10 h. A second blood sample was taken after 2 h to determine plasma glucose. Standard World Health Organization criteria for the diagnosis of diabetes mellitus were used: fasting plasma glucose 7.0 mmol/L or 2-h plasma glucose 11.1 mmol/L (17). Plasma glucose levels were measured enzymatically with a glucose oxidase method using the Olympus AU600 auto-analyser.
Hypertension Status.
Hypertension was defined as systolic BP greater than or equal to 140 mmHg or diastolic BP greater than or equal to 90 mmHg, or use of medication for hypertension irrespective of the BP. BP was measured in a seated position after the participant had rested for at least 5 min using an appropriately sized cuff. In one of the states, BP was measured using a standard mercury sphygmomanometer. Two readings were taken, with a third if the first two differed by more than 10 mmHg. In the remaining states, BP was measured using the Dinamap semiautomatic oscillometric recorder, where three readings were taken at 1-min intervals. To obtain the final measure of BP, the mean of the first two readings was calculated, unless the difference between these readings was greater than 10 mmHg, in which case the mean of the two closest of three measurements was used. Based on a comparison study of readings using the sphygmomanometer and the Dinamap, an adjustment was made to all diastolic BP readings recorded in the state using the sphygmomanometer.
Statistical Analysis
All analyses were conducted using Stata version 6.0 (Stata Corporation, College Station, TX, 1999) survey commands for analyzing complex survey data. The survey design included seven strata and 42 primary sampling units, and all prevalence estimates were weighted to represent the noninstitutionalized Australian population thereby accounting for nonresponse and producing nationally representative estimates.
The prevalence rates of hematuria, proteinuria, and reduced GFR were calculated stratified by age, gender, and risk factors for renal disease (diabetes mellitus and hypertension). Differences between subjects were tested by 2-tailed unpaired t test for continuous data and 
2 test for categorical data. Age was modeled as a categorical variable (25 to 44 yr, 55 to 64 yr, 65 yr or older). The associations between age, gender, hypertension, and diabetes status, and indicators of kidney disease were determined by computing odds ratios and their respective 95% confidence intervals by logistic regression.
|
Results |
|---|
|
TopAbstractIntroductionParticipants and MethodsResultsDiscussionReferences |
|---|
Prevalence of Indicators of Kidney Damage
Proteinuria.
Levels of urine protein to creatinine ratio of 0.2 mg/mg or greater were detected in 2.4% of participants (Table 1). The prevalence was similar in men and women, but increased with age from 0.8% in the 25 to 44 yr age group to 6.6% in those 65 yr of age and over (P < 0.001 for trend across age groups). The increase in prevalence of proteinuria with increasing age was seen in both men and women (P < 0.001 and P = 0.013, respectively, for trend across age groups). Levels of urine protein to creatinine ratio 0.80 mg/mg or greater (approximately 1 g/d urine protein excretion) were detected in 0.4% of participants, and were similar in men and women. The prevalence increased from 0.1% in the 25 to 44 yr age group to 1.0% in those 65 yr of age and over (P = 0.010 for trend across age groups). The increase in prevalence of proteinuria with increasing age was seen in both men and women (P < 0.001 and P = 0.011, respectively, for trend across age groups).
|
|
|
90ml/min per 1.73 m2) was present in 0.9% (95% CI: 0.7%, 1.1%); stage 2 kidney disease (proteinuria and/or hematuria with GFR 60 to 89 ml/min per 1.73 m2) in 2.0% (95% CI: 1.6%, 2.5%); stage 3 kidney disease (GFR 30 to 59 ml/min per 1.73 m2) in 10.9% (95% CI: 8.4%, 13.3%); stage 4 kidney disease (GFR 15 to 29 ml/min per 1.73 m2) in 0.3% (95% CI: 0.2%, 0.5%); and stage 5 kidney disease (GFR <15 ml/min per 1.73 m2) in 0.003% (95% CI: 0.000%, 0.009%).
Overlap between Indicators of Kidney Damage
The proportion of proteinuria found in the absence of either hematuria or reduced GFR <60 ml/min per 1.73 m2 was 46.8%; 34.8% of participants with proteinuria also had a reduced GFR, 12.0% also had hematuria and 6.4% had both a reduced GFR and hematuria (Figure 1). The majority of hematuria occurred in the absence of other indicators of kidney damage; 12.1% of participants with hematuria also had a reduced GFR, 5.7% also had proteinuria, and 3.1% had both a reduced GFR and proteinuria. In participants with a reduced GFR, 86.6% occurred without either proteinuria or hematuria; 7.0% of participants also had proteinuria, 5.1% also had hematuria, and 1.3% had both proteinuria and hematuria.
|
|
Hypertension.
The prevalence of proteinuria was fivefold greater in hypertensive participants compared with those with normal BP (5.5%; 95% CI: 4.0%, 7.1% versus 1.1%; 95% CI: 0.7%, 1.5%; P < 0.001). The prevalence of hematuria was similar in those with and without hypertension (5.0%; 95% CI: 3.9%, 6.0% versus 4.5%; 95% CI: 3.6%, 5.4%; P = 0.44). A reduced GFR <60 ml/min per 1.73 m2 was fivefold more prevalent in those with hypertension compared with those without (27.3%; 95% CI: 23.0%, 31.6% versus 4.7%; 95% CI: 3.5%, 6.0%; P < 0.001).
|
Discussion |
|---|
|
TopAbstractIntroductionParticipants and MethodsResultsDiscussionReferences |
|---|
Proteinuria was detected in 2.4% of participants by measuring the protein to creatinine ratio in a morning spot urine sample. Two previous population-based studies have examined the prevalence of proteinuria in adults. Iseki et al. detected proteinuria, as defined by a dipstick result of trace or greater, in 4.0 to 6.0% of men and 2.5 to 7.0% of women in a study of 107,192 Japanese volunteers (7). A similar prevalence, ranging from 1% in 35 to 44 yr olds to 6% in 55 to 64 yr men, was found in a study of US volunteers, which used the Quantitest to detect proteinuria (19). Given that dipstick detection of proteinuria has a low specificity and is likely to overestimate true prevalence (20), these data are consistent with the AusDiab results.
Proteinuria is the cardinal manifestation of overt diabetic nephropathy and hypertensive renal damage. Consistent with this, the prevalence of proteinuria was fourfold higher in diabetics and fivefold higher in those with hypertension. The presence of proteinuria indicates a significant risk of progressive kidney damage. In the general population, participants found to have proteinuria by dipstick on screening examination have been reported to incur a 14-fold relative risk of end-stage renal failure during 10 yr of follow-up (7). For those with established renal disease, proteinuria is an important predictor of the risk of progression (21) and mortality (19). Proteinuric renal disease is amenable to intervention with readily available therapies. Interventions including glycemic control (22), treatment of hypertension (23,24) and interruption of the renin-angiotensin system with converting enzyme inhibitors (25,26) or angiotensin II receptor antagonists (27–29) are known to be effective in retarding progression of diabetic nephropathy and other proteinuric renal diseases.
Hematuria was detected by dipstick in 5.2% of participants and confirmed in 4.6% by microscopy or repeat dipstick: 2.0% of men and 7.2% of women. Much of the higher prevalence in younger women is likely to be due to urinary sepsis and contamination from menstrual blood. Excluding cases of isolated hematuria in the setting of a confirmed urinary tract infection, the prevalence of hematuria was found to be 4.4 to 2.0% in men and 6.7% in women. The additional exclusion of cases of isolated hematuria in women under the age of 50 yr due to possible menstrual contamination results in a prevalence of hematuria of 2.5 to 2.0% in men and 3.0% in women. The prevalence reported in previous population-based studies has varied according to the definition of hematuria. One study based on dipstick results of 1+ or greater reported that 2.8% of men and 11.0% of women had hematuria (7). In contrast, the prevalence of hematuria based on microscopy results of more than ten red blood cells per high power field has been reported as only 0.6% in men and 1.4% in women (30).
On a population basis, hematuria is a less powerful predictor of progressive renal disease than is proteinuria. Participants with dipstick hematuria detected on screening were reported to incur a threefold relative risk of developing end-stage renal failure within 10 yr (7). This is likely because most causes of hematuria, with the exception of glomerulonephritis, are not recognized causes of renal failure: urinary tract infection, renal calculi, prostatic disease, urinary tract tumors, and thin basement membrane disease. Furthermore, the excess of hematuria seen in women of reproductive age also points to menstrual contamination as a likely contributor.
Renal function was assessed by estimated GFR and significant impairment of renal function was highly prevalent, particularly among the elderly and those with hypertension. The largest population-based studies of renal function have used serum creatinine as a measure of renal function (31,32). As in this study, renal impairment was strongly correlated with older age and the presence of hypertension. Elevated serum creatinine was detected in 3.0% of the adult population in NHANES III (31) and in 8.0 to 8.9% of participants in the Framingham cohort (32). However, serum creatinine is known to underestimate the prevalence of renal impairment (33). Prevalence of renal impairment based on GFR estimates was 6.3% in the adult population in NHANES III (34), although this study used serum creatinine cut-points as estimates of GFR <60 ml/min per 1.73 m2 rather than Cockcroft-Gault estimated GFR calculated for each individual participant, which was performed in this study. The use of such serum creatinine cut-points has been shown to underestimate the prevalence of reduced GFR compared with the use of both the Cockcroft-Gault and Modification of Diet in Renal Diseases formulas (35). The prevalence of GFR <60 ml/min based on Cockcroft-Gault formula in nondiabetic adults from NHANES III was 14%, and although similar to the findings of this study was not adjusted by body surface area and therefore was not completely comparable (35).
Impairment of GFR has many implications for both the individual and the population, with even mild impairment of GFR having been associated with an increased cardiovascular risk (36–38) and increased mortality rate (32,39). Awareness of a reduced GFR is therefore important to enable targeting of cardiovascular risk factors and treatment of hypertension in particular, which is associated with a reduction in the progression of kidney damage. Reduced GFR also has significant implications for drug prescription and drug toxicities (40).
Proteinuria, microscopic hematuria, and reduced GFR are frequently asymptomatic. Data on the participant’s prior knowledge of renal impairment, proteinuria, or hematuria were not collected. However, knowledge of diabetes and hypertension was assessed and approximately half of those found to be hypertensive or have diabetes mellitus were previously unaware of their diagnosis. Thus, it is probable that many of the subjects were found to have one or more indicators of kidney damage for the first time. It is likely that most people in the community with indicators of kidney disease will remain unaware of their abnormality unless it is detected through screening.
The effect of intervention for those with indicators of kidney disease remains incompletely understood. However, it is clear that some forms of intervention are effective in either slowing or preventing progression toward ESRD. Individuals with hematuria may benefit from specific investigations to determine the etiology, as some processes, such as glomerulonephritis and cancer, may be amenable to therapy. Proteinuric nephropathies, and diabetic nephropathy in particular, may be responsive to blockade of the renin-angiotensin system (25–29). Individuals with reduced renal function from any cause have been shown to benefit from frequent follow-up and monitoring (41). Those with hypertension are less likely to suffer renal failure when their hypertension is treated (23). Thus, individuals with one or more indicators of kidney damage may benefit from intervention. Effective interventions are widely available in Australia and in most developed countries. The major barrier to appropriate management therefore appears to be ignorance of the problem.
The AusDiab Kidney Study has documented a high prevalence of kidney damage in the general Australian adult population, and a similar prevalence is likely to exist in most developed countries. How kidney damage evolves over time and what should be done about it remain to be better defined. The effectiveness of screening for indicators of kidney damage similarly requires appropriate assessment. Given the increasing burden of ESRD worldwide, acquisition of this information should be a global priority.
|
Acknowledgments |
|---|
|
References |
|---|
|
TopAbstractIntroductionParticipants and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  E. Noble, D. W. Johnson, N. Gray, P. Hollett, C. M. Hawley, S. B. Campbell, D. W. Mudge, and N. M. Isbel The impact of automated eGFR reporting and education on nephrology service referrals Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3845 - 3850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chen, W. Chen, H. Wang, X. Dong, Q. Liu, H. Mao, J. Tan, J. Lin, F. Zhou, N. Luo, et al. Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China Nephrol. Dial. Transplant., October 24, 2008; (2008) gfn604v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Huttner, E. U. Graefe-Mody, B. Withopf, A. Ring, and K. A. Dugi Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers J. Clin. Pharmacol., October 1, 2008; 48(10): 1171 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Sumaili, J.-M. Krzesinski, C. V. Zinga, E. P. Cohen, P. Delanaye, S. M. Munyanga, and N. M. Nseka Prevalence of chronic kidney disease in Kinshasa: results of a pilot study from the Democratic Republic of Congo Nephrol. Dial. Transplant., August 20, 2008; (2008) gfn469v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. White, K. McGeechan, M. Jones, A. Cass, S. J. Chadban, K. R. Polkinghorne, V. Perkovic, and P. J. Roderick Socioeconomic Disadvantage and Kidney Disease in the United States, Australia, and Thailand Am J Public Health, July 1, 2008; 98(7): 1306 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Carter, S. E. O'Riordan, G. L. Eaglestone, M. P. Delaney, and E. J. Lamb Chronic kidney disease prevalence in a UK residential care home population Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1257 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Roderick, R. J. Atkins, L. Smeeth, D. M. Nitsch, R. B. Hubbard, A. E. Flectcher, and C. J. Bulpitt Detecting chronic kidney disease in older people; what are the implications? Age Ageing, March 1, 2008; 37(2): 179 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Richards, K. Harris, M. Whitfield, D. O'Donoghue, R. Lewis, M. Mansell, S. Thomas, J. Townend, M. Eames, and D. Marcelli The impact of population-based identification of chronic kidney disease using estimated glomerular filtration rate (eGFR) reporting Nephrol. Dial. Transplant., February 1, 2008; 23(2): 556 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Orth and S. I. Hallan Smoking: A Risk Factor for Progression of Chronic Kidney Disease and for Cardiovascular Morbidity and Mortality in Renal Patients Absence of Evidence or Evidence of Absence? Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 226 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. T. Raymond, D. Zehnder, S. C. H. Smith, J. A. Stinson, H. Lehnert, and R. M. Higgins Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3214 - 3220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ferris, S. L. Hogan, H. Chin, D. A. Shoham, D. S. Gipson, K. Gibson, S. Yilmaz, R. J. Falk, and J. C. Jennette Obesity, Albuminuria, and Urinalysis Findings in US Young Adults from the Add Health Wave III Study Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1207 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ludlow, G. Luxton, and T. Mathew Effects of fluoridation of community water supplies for people with chronic kidney disease Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2763 - 2767. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Perkovic, T. Ninomiya, H. Arima, M. Gallagher, M. Jardine, A. Cass, B. Neal, S. MacMahon, and J. Chalmers Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2766 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Klebe, J. Irving, P. E. Stevens, D. J. O'Donoghue, S. de Lusignan, R. Cooley, H. Hobbs, E. J. Lamb, I. John, R. Middleton, et al. The cost of implementing UK guidelines for the management of chronic kidney disease Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2504 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. MacGregor How common is early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix8 - ix18. [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, L. Zuo, G. Xu, F. Wang, M. Wang, S. Wang, J. Lv, L. Liu, and H. Wang Community-based screening for chronic kidney disease among populations older than 40 years in Beijing Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1093 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Viktorsdottir, R. Palsson, M. B. Andresdottir, T. Aspelund, V. Gudnason, and O. S. Indridason Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults Nephrol. Dial. Transplant., September 1, 2005; 20(9): 1799 - 1807. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
